CORDIS
EU research results

CORDIS

English EN
Neurobiology and Treatment of Adolescent Female Conduct Disorder: The Central Role of Emotion Processing

Neurobiology and Treatment of Adolescent Female Conduct Disorder: The Central Role of Emotion Processing

Objective

Conduct Disorder (CD) and Oppositional Defiant Disorder with symptoms of Conduct Disorder (which is included among the abbreviation “CD” throughout the proposal) has a highly negative impact for the affected individual as well as for families and society. Although the number of females exhibiting serious aggressive behaviours is growing, the majority of studies on aetiology and treatment of CD have focused on male subjects only, despite strong evidence for a differential neurobiological basis of female CD. The key aims of the FemNAT-CD consortium are to identify biomarkers and to study disease mechanisms from pre- to postpubertal female CD as well as new psychological and pharmacological treatment options for female adolescent CD targeting emotion processing abilities. With the present proposal, we aim at clarifying the phenomenology and neurobiology of female CD from pre-puberty to post-puberty. We will study the role of genetic and environmental risk factors on female CD, related psychopathology, brain structure and function, HPA axis and autonomic nervous system (ANS) disturbance to elicit CD specific endophenotypes and its biomarkers. We will describe the clinical, neuronal and neurocognitive phenotype of female CD from pre- to postpuberty and related neuroendocrine and ANS function as well as moderating, mediating and direct risk factors to identify distinct homogeneous subtypes to guide targeted future treatment approaches. We translate knowledge of neuropsychological and neurobiological characteristics into targeted intervention by performing a randomised controlled trial of an innovative 16-week DBT-CD-A psychological treatment program focussing on emotion processing. The effect oxytocin and serotonin on neural function underlying emotion processing and aggression will be studied in a female animal model and two proof of concept pharmaco-challenge studies. We also target several societal and education objectives. Our consortium brings together strong clinical and basic science expertise on paediatric CD, including a number of SMEs and a professional management company.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

JOHANN WOLFGANG GOETHE-UNIVERSITATFRANKFURT AM MAIN

Address

Theodor W Adorno Platz 1
60323 Frankfurt Am Main

Germany

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 1 383 778,89

Administrative Contact

Christine Freitag (Prof.)

Participants (20)

Sort alphabetically

Sort by EU Contribution

Expand all

UNIVERSITAETSKLINIKUM AACHEN

Germany

EU Contribution

€ 731 806,32

STICHTING VU

Netherlands

EU Contribution

€ 309 373,02

UNIVERSITY OF SOUTHAMPTON

United Kingdom

EU Contribution

€ 495 413,70

UNIVERSITAT BASEL

Switzerland

EU Contribution

€ 569 136,25

UNIVERSITATSKLINIKUM HEIDELBERG

Germany

EU Contribution

€ 587 310

THE UNIVERSITY OF BIRMINGHAM

United Kingdom

EU Contribution

€ 509 686,20

THE PROVOST, FELLOWS, FOUNDATION SCHOLARS & THE OTHER MEMBERS OF BOARD OF THE COLLEGE OF THE HOLY & UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN

Ireland

EU Contribution

€ 22 130,90

UNIVERSITAET REGENSBURG

Germany

EU Contribution

€ 254 529

FUNDACIO MUTUA DE TERRASSA PER A LA DOCENCIA I RECERCA BIOMEDICA I SOCIAL FUNDACIO PRIVADA CATALANA

Spain

EU Contribution

€ 42 290,64

FUNDACION VASCA DE INNOVACION E INVESTIGACION SANITARIAS

Spain

EU Contribution

€ 62 081

SZEGEDI TUDOMANYEGYETEM

Hungary

EU Contribution

€ 32 096

ETHNIKO KAI KAPODISTRIAKO PANEPISTIMIO ATHINON

Greece

EU Contribution

€ 49 515,01

GENEWAKE GMBH

Germany

EU Contribution

€ 11 050,70

VARIONOSTIC GMBH

Germany

EU Contribution

€ 404 087

DAACRO GMBH & CO KG

Germany

EU Contribution

€ 114 472

GABO:MI GESELLSCHAFT FUR ABLAUFORGANISATION:MILLIARIUM MBH & CO KG

Germany

EU Contribution

€ 170 266

CARDIFF UNIVERSITY

United Kingdom

EU Contribution

€ 31 370

ARTTIC

France

EU Contribution

€ 120 963

GENXPRO GMBH

Germany

EU Contribution

€ 97 885,37

STICHTING VUMC

Netherlands

Project information

Grant agreement ID: 602407

Status

Closed project

  • Start date

    1 September 2013

  • End date

    28 February 2018

Funded under:

FP7-HEALTH

  • Overall budget:

    € 8 058 960,06

  • EU contribution

    € 5 999 241

Coordinated by:

JOHANN WOLFGANG GOETHE-UNIVERSITATFRANKFURT AM MAIN

Germany